Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
← catalyst calendarNCT07162181 · readout ≤ 1,381 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
13estimated
Sites
6
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-07 | actual | When the study began enrolling |
| Primary completion | May 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | May 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-09-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Lymphoma, Non-Hodgkin
- Leukemia, Lymphocytic, Chronic, B-Cell
- B-cell Lymphoma
Intervention
- Drug: Pirtobrutinib — also filed as Loxo-305, LY3527727
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants with Grade 3 or Higher Treatment-emergent Adverse Events
measured Day 1 through 28 days after last dose or start of new anticancer therapy
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed